EMA Panel Recommends Approval for Merck's Injectable Keytruda

A key committee of the European Medicines Agency has recommended approval for an injectable version of Merck's cancer drug Keytruda, paving the way for potential authorization across the European Union. This subcutaneous formulation aims to offer a more convenient alternative to intravenous administration for patients with various cancers. The recommendation, issued on September 19, 2025, follows positive clinical data and could enhance treatment accessibility in Europe.

Lawsuits claim Tylenol use in pregnancy causes autism

October 02, 2025 Reported by AI

More than 100 lawsuits have been filed against acetaminophen manufacturers, including Johnson & Johnson, alleging that the drug's use during pregnancy increases the risk of autism and ADHD in children. These legal actions stem from scientific studies showing associations between prenatal exposure and neurodevelopmental disorders. The cases highlight growing concerns over the safety of a widely used pain reliever.

Pfizer stock rises after aligning with Trump on drug pricing

October 01, 2025 Reported by AI

Pfizer's shares climbed on Monday after the company expressed support for former President Donald Trump's proposal to allow imports of lower-priced drugs from Canada. This stance marks a shift for the pharmaceutical giant, which has historically opposed such measures. The move comes amid ongoing debates over U.S. drug costs.

FDA Grants Accelerated Approval for First Barth Syndrome Treatment

The U.S. Food and Drug Administration has granted accelerated approval to Forzinity, the first treatment for Barth syndrome, a rare X-linked genetic disorder primarily affecting males. Developed by Stealth Biotherapeutics, the therapy targets mitochondrial dysfunction underlying the condition, offering new hope for patients with this life-threatening disease. This milestone follows years of advocacy and highlights progress in addressing ultra-rare disorders.